Alzheimer's Disease
Suvorexant acutely effective in reducing Alzheimer’s-related biomarkers
PHILADELPHIA — In cognitively healthy but sleep-poor adults in midlife, treatment with 20 mg suvorexin led to acute decreases in Alzheimer’s-related biomarkers compared with 10 mg of the drug and placebo, according to a presenter.
Eliminating these 14 risk factors may prevent nearly half of dementia cases
PHILADELPHIA — Tackling 14 risk factors for dementia beginning in childhood could prevent or delay nearly half of cases, according to a report from the Lancet Commission presented at the Alzheimer's Association International Conference.
Processed red meat intake linked to 14% higher risk for dementia
PHILADELPHIA — Individuals who consumed about two weekly servings of processed red meat had a 14% higher risk for dementia, as well as accelerated cognitive aging, vs. those who ate less than three servings a month, according to research.
Asthma associated with increased risk for Alzheimer’s disease
The incidence and prevalence of Alzheimer’s disease was positively associated with an increased risk for asthma, according to a study published in The Journal of Allergy and Clinical Immunology.
Liraglutide may slow cognitive decline, brain volume loss in patients with AD dementia
PHILADELPHIA — Treatment with liraglutide appeared to reduce cognitive decline and slow volume loss in several areas of the brain after 1 year among individuals with mild to moderate Alzheimer’s dementia, according to new research.
Blood test for AD pathology demonstrates higher predictive accuracy than clinicians
PHILADELPHIA — Utilization of a specialized blood test to detect Alzheimer’s-related pathology led to higher diagnostic accuracy compared to health care professionals’ identification, data show.
Annovis secures US patent for buntanetap
Annovis Bio Inc. has secured a U.S. patent for methods of treating acute traumatic brain injuries with its lead drug candidate, an oral, small molecule neurotoxic protein inhibitor.
Lantheus acquires Meilleur, including global rights to PET imaging agent for Alzheimer’s
Lantheus Holdings Inc. has announced the acquisition of Meilleur Technologies Inc., which includes the transfer of its rights to an amyloid-beta positron emission tomography imaging agent.
FDA grants fast-track designation to cellular therapy for mild Alzheimer’s
The FDA has granted fast-track designation to a proprietary, scalable, allogeneic, investigational cellular therapy in development to address symptoms of mild Alzheimer’s disease, according to the manufacturer.
NYU Langone tops list again as best US hospital for neurology, neurosurgery
NYU Langone was again the top hospital in the United States for neurology and neurosurgery, according to the latest annual Best Hospitals Survey issued by U.S. News & World Report.